NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients

NCT01374308 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

BIOLOGICAL: NASVAC
DRUG: Pegylated interferon alpha 2b

Sponsor

Clinical Research Organization, Dhaka, Bangladesh